



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Mrs. Zarzokimi, (Assistant Drugs Inspector (Food and Drugs))
Champhai-796321 Mizoram
- Serial No. and date of Inspector's memorandum : 379/25 , 23-JAN-2026
- Number of Sample : NIL
- Date of receipt : 02-FEB-2026
- Names of drugs purporting to be contained in the sample : CIPROFLOXACIN TABLETS IP 250 mg (Ciprodac 250)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2026-26/1285	27/58	CT23019	Sep-2023 Aug-2026	NA	CADILA PHARMACEUTICALS LIMITED, 1389, Dholka-382225, Dist. Ahmedabad

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 28-Apr-2026 To 04-May-2026

COMPOSITION : Each film-coated tablet contains:
Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Ciprofloxacin Hydrochloride.	NA
3	Average weight	0.3322 g	NA
4	Uniformity of weight	Complies.	±5% of avg. wt.
5	Dissolution	Complies.	NLT 80 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

